FierceMedicalDevices Editors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this year’s winners based on their top management teams, notable financial backing and promising technologies and market opportunities. TYRX was chosen as one of the Fierce 15 based, in part, on its creativity and innovations in the industry.
“We took a close look at TYRX because they came up with something that is so straightforward and simple, but truly advances the standard of care,” Mr. Hollmer said. “By sealing a pacemaker or defibrillator in the company’s AIGISRx Antibacterial Envelope and then implanting both, a patient’s risk of infection is drastically reduced. And the company has generated serious revenue already.”
The AIGISRx Envelope is specifically designed to aid in the stabilization of cardiac implantable electronic device placement as well as to help reduce surgical-site infections associated with CIEDs. AIGISRx products contain the antimicrobial agents rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including MRSA.
Learn more about TYRX.
